Aurobindo Pharma Receives Final FDA Approval for Pirfenidone Generic for Idiopathic Pulmonary Fibrosis
FDA Final Approval and Aurobindo Pharma's Market Entry
The U.S. Food and Drug Administration (FDA) has granted final approval for Aurobindo Pharma Limited's 267mg Pirfenidone capsule generic drug (ANDA 212597) on April 20, 2026. Pirfenidone is a key antifibrotic agent that slows the progression of Idiopathic Pulmonary Fibrosis (IPF) by inhibiting collagen synthesis through the blockade of Transforming Growth Factor-beta (TGF-beta) and Tumor Necrosis Factor-alpha (TNF-alpha). This approval marks a milestone for Aurobindo Pharma in expanding its portfolio in the U.S. respiratory generic market and will significantly improve treatment access for patients with IPF.
Patent Expiration of the Blockbuster Esbriet and Market Restructuring
The originator of Pirfenidone, Esbriet from Roche, was a blockbuster drug, generating over $1 billion in annual revenue from 2018 to 2022, before its patent expiration. However, with the expiration of its U.S. patent exclusivity in 2022, several generic competitors, including Sandoz and Teva, entered the market, causing Esbriet's 2023 revenue to plummet to $229 million and recently falling below $100 million. Aurobindo Pharma's entry into the market will further intensify price competition, accelerating the erosion of the originator's market share and triggering competition for market share within the generic market.
Competitive Landscape with Ofev and the Characteristics of Targeted Therapy
The IPF treatment market is currently dominated by Pirfenidone and Ofev (Nintedanib) from Boehringer Ingelheim, a multi-kinase inhibitor. Ofev works by simultaneously targeting Platelet-Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor (FGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR). The lower cost of Pirfenidone generics provides a strong alternative option for patients burdened by the high cost of Ofev, and is expected to have a positive social impact by alleviating the burden on healthcare finances.
Global IPF Market Size and Mid- to Long-Term Outlook
The global IPF treatment market has reached approximately $5.39 billion (approximately 7 trillion KRW) in 2026, driven by the aging population and advancements in diagnostic technology, and is expected to continue growing at an annual rate of over 8%, reaching $9.79 billion in 2033. In this growing market, late-entrant generic manufacturers face the challenge of targeting niche markets with their large-scale production capabilities and price competitiveness. Aurobindo Pharma is expected to focus on the price-sensitive U.S. public healthcare market by leveraging its strong Active Pharmaceutical Ingredient (API) manufacturing capabilities in India.
With Aurobindo Pharma securing FDA approval for its Pirfenidone generic on April 20, 2026, generic competition within the $5.39 billion global IPF market will be intensified. Amidst the rapid decline of Roche's Esbriet, which once generated $1 billion in annual revenue, following patent expiration, this approval is expected to further accelerate the shift towards generics in the market. While Boehringer Ingelheim's Ofev currently leads the market, the entry of Indian generic manufacturers with their cost advantages will exert downward pressure on prices across the high-priced drug market. From an investor perspective, it is crucial to analyze whether Aurobindo Pharma's API internalization will serve as a long-term margin defense mechanism amidst intensifying price competition. From an R&D perspective, securing a next-generation IPF pipeline with novel mechanisms that overcome the limitations of existing generics and achieving successful Phase 3 clinical trials will be key to future market entry.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA212597